SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...
– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...
– Additional data presented at the 18th International Conference on Advanced Technologies & Treatments for Diabetes – Results published in NEJM demonstrate significant improvements in time in range ...
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2™ insulin pump with Control-IQ+ automated ...
The US Food and Drug Administration (FDA) has expanded the indication for Tandem Diabetes Care’s Control-IQ+ Technology to include people with type 2 diabetes (T2D). The next-generation Control-IQ+ ...
Tandem Diabetes Care Inc. reported that its next-generation automated insulin delivery algorithm, Control-IQ+ technology (Control-IQ+), is cleared by the U.S. FDA for use by people with type 2 ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world’s smallest, durable ...
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced publication by The New England Journal of Medicine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results